Raymond James raised the price target for the Dyne Therapeutics Inc (NASDAQ:DYN) stock from “an Outperform” to “a Strong buy”. The rating was released on February 27, 2023, according to finviz.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Dyne Therapeutics Inc (NASDAQ:DYN) raised 12.85% to close Friday’s market session at $11.02, higher as compared to yesterday’s close. The stock price fluctuated between $9.82 and $11.03 throughout the trading session with the volume trading being 590663 shares, which represented a significant variation when compared to the three months average volume of 542.94K shares. The firm’s stock price fluctuated 26.67% within the last five trades and 47.72% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -19.56% in the last 6 months and 1.75% was added to its value over the previous 3 months. DYN stock is trading at a margin of 36.25%, 28.26% and -0.64% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, DYN deals in the Healthcare domain. The stock is trading -29.36 percent below its 52-week high and 72.19 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -23.6. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Dyne Therapeutics Inc’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 0.00 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $676.41 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 4.44, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 48.20 percent of Dyne Therapeutics Inc shares are owned by insiders, and 61.37 percent are held by financial institutions. HIGH SUSANNA GATTI, the Chief Operating Officer at Dyne Therapeutics Inc (DYN) has sold 9,939 shares of firm on Nov 02 at a price of $7.40 against the total amount of $73549.0. In another inside trade, Brumm Joshua T, of Dyne Therapeutics Inc (NASDAQ:DYN) sold 12,032 shares of the firm on Sep 18 for a total worth of $0.11 million at a price of $9.41. An inside trade which took place on Sep 18, Chief Operating Officer of Dyne Therapeutics Inc HIGH SUSANNA GATTI sold 2,672 shares of firm against total price of $25144.0 at the cost of $9.41 per share.